Precision Medicine in the Prostate Cancer Care Pathway
Recruiting now
Conditions studied: Prostate Cancer, Genetic Predisposition
In brief
This study aims to evaluate the use of a prostate cancer specific predisposition genetic panel test in men with / at high risk of prostate cancer. The genetic test will analyse men's DNA samples for the presence of mutations in rare genes as well as common genetic variation to provide men with information about their risk of prostate cancer. This study will evaluate the clinical impact of the test on risk assessment and clinical management in terms of screening and treatment.
Key facts
- Study ID
- NCT04763317
- Run by
- Institute of Cancer Research, United Kingdom
- People needed
- 3000
- Starts
- 2019-02-14
- Expected to finish
- 2034-12-01
- Last updated by the study team
- 2025-12-16
Who can join
Age: 30 and older, up to 70. Sex: male. Healthy volunteers: not accepted.
You may qualify if…
- Affected cohort:
- Affected with PrCa < 60 years or
- Affected with metastatic castration resistant PrCa (mCRPC) at any age or Aggressive PrCa Gleason 4+4 or higher <70 years
- Affected with family history defined as three or more cases any age (FDR or SDR)
- Unaffected cohort: (This cohort is no longer recruiting, it has completed recruitment)
- Aged >30 and with a family history defined as:
- FDR diagnosed < 70
- 2 or more cases in First or Second Degree Relatives (FDR/SDR) with one case diagnosed < 70 years
- 3 or more cases at any age (on same side of family)
You may not qualify if…
- • WHO performance status 4
Where it is running
- Royal Marsden Hosital, — Sutton, England, United Kingdom (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.